September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Intravitreal Autologous Bone Marrow Derived Stem Cells in Ischemic Maculopathy
Results after 12 Months Follow-up
Author Affiliations & Notes
  • Felipe Placeres Borges
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
  • Rubens C Siqueira
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
  • Murilo Wendeborn Rodrigues
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
  • Amanda Jardim Dos Santos
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
  • Andre Messias
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
  • Rodrigo Jorge
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships   Felipe Borges, None; Rubens Siqueira, None; Murilo Rodrigues, None; Amanda Dos Santos, None; Andre Messias, None; Rodrigo Jorge, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3741. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Felipe Placeres Borges, Rubens C Siqueira, Murilo Wendeborn Rodrigues, Amanda Jardim Dos Santos, Andre Messias, Rodrigo Jorge; Intravitreal Autologous Bone Marrow Derived Stem Cells in Ischemic Maculopathy
      Results after 12 Months Follow-up. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3741.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the effects of a single intravitreal injection of autologous bone-marrow stem cells (ABMSC) in in retinal vascular diseases with ischemic maculophaty

Methods : Prospective, single blind, phase I/II non-randomized clinical trial (ClinicalTrials.gov Identifier: NCT01518842), including 15 patients (15 eyes) with ischemic maculopathy due to diabetic retinopathy (DR), central retinal vein occlusion (CRVO) or central retinal artery occlusion (CRAO) showing best-corrected visual acuity (BCVA) of 0.4 logMAR or worse, absence of active neovascularization, media opacity, prior vitrectomy and ocular pathologies. Patients underwent intravitreal injection of approximately 106(0,1mL) autologous bone marrow-derived mononuclear cells (containing CD 34+ cells) and were evaluated before injection (baseline), and monthly during follow-up. A comprehensive ophthalmological evaluation was performed, including BCVA measurement,full field electroretinography, multifocalelectroretinography,microperimetry, fluorescein angiography, SD-OCT and adaptive optics imaging.

Results : So far, 16 eyes were treated, 9 completed the 12-month follow-up, 2 were excluded for diabetic medical complications. From the treated eyes, 2 had macular ischemia due to arterial occlusion, 5 due to venous occlusion and 9 due to DR. Parameters were analyzed for months 1,3, 6 and 12. No significant changes were observed for all parameters. No significant ocular or systemic adverse effects were observed. There was a small but no significant improvement on BCVA in logMAR , P = 0.3655, P = 0.3655 and P = 0.3743 (1, 3 and 12 months respectively).

Conclusions : Intravitreal injection of autologous bone-marrow stem cells (ABMSC) seem to be safe in eyes with ischemic maculopathy, and in this small cohort was associated with no significant changes in twelve months. A larger number of cases and a longer follow-up are needed to confirm these findings.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×